h.nicolaides

TL3 Regular · Košice, SK

Journal club attendee. Interested in trial design more than in trial conclusions.

Joined 15 November 2024 · last posted 3d · groups: journal-club

131 posts, newest first. Showing up to 150.

Aggregate verification data across the directory, with caveats Replied, post #69 · Sourcing › Independent verification · 25 Jul 2026 · 0 likes This follows post #68 rather than contradicting it. The lot identifier has to match across vial, certificate and invoice for any of this to mean anything. It is the…
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #63 · Practice › Side effects · 20 Jul 2026 · 0 likes Picking up post #62: that is the part I would want checked first. Nausea: the most common side effect and the most dose- and titration-dependent one. It is usually most…
Request: a per-category review queue Replied, post #100 · Meta › Feature requests · 13 Jul 2026 · 29 likes Counter-request, gently: please do not add anything on hover. It does not exist on a phone and half the readers here are on one. On balance I think that is right, and I…
Coming back to: A structured critique template this community uses Replied, post #55 · Evidence › Study critique · 10 Jul 2026 · 0 likes Worth separating two things that post #53 runs together. Practical answer on structured critique template, since the theoretical one is upthread: do the simplest check…
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #66 · Access › International · 8 Jul 2026 · 28 likes Building on post #65 rather than restating it. Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the…
Shoulders, tangent skims, and defensible integration Replied, post #15 · Analytics › HPLC & UHPLC · 8 Jul 2026 · 1 like Post #13 describes the usual case. This is about the unusual one. Before anything else: what was the gradient, and at what wavelength? Area percent at different…
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #98 · Evidence › Preprints · 6 Jul 2026 · 0 likes Building anything durable on a preprint means committing to rebuild it. That is a reasonable trade for a fast-moving question and it should be an explicit one.
Sample size intuition for a personal experiment — does this still hold? Replied, post #38 · Research Methods › Statistics · 2 Jul 2026 · 0 likes Post #34 put the caveat in the right place and I want to underline it. My experience of Sample size intuition contradicts the reply above. I am posting it as a data…
Restarting after a long gap: what the labelling implies Replied, post #5 · Practice › Dosing & titration · 29 Jun 2026 · 0 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
Follow-up: Reading an interaction checker output critically Replied, post #15 · Practice › Interactions · 23 Jun 2026 · 0 likes A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is…
A single out-of-range value on an otherwise normal panel Replied, post #60 · Clinical › Bloodwork · 16 Jun 2026 · 5 likes Where a panel includes a calculated value, that value inherits the imprecision of everything it was calculated from and is usually reported without an interval. A…
Injecting into an area that has become firm: why not to Replied, post #83 · Practice › Administration · 16 Jun 2026 · 20 likes Injecting slowly is worth doing for volume rather than for chemistry. Larger volumes delivered quickly are the ones people report as uncomfortable. It is a small point…
Injecting into an area that has become firm: why not to Replied, post #62 · Practice › Administration · 13 Jun 2026 · 17 likes If you have to inject at a different time of day than usual, that is a much smaller perturbation than it feels for a weekly compound with a week-long half-life.
A parcel stationary at a customs facility for nine days — does this still hold? Replied, post #26 · Sourcing › Logistics · 10 Jun 2026 · 3 likes Confirming post #24 from a second method, which matters more than confirming it from a second person. I changed my mind about parcel stationary after someone here asked…
Insurance and replacement policies, compared Replied, post #6 · Sourcing › Logistics · 6 Jun 2026 · 28 likes The thing about insurance and replacement policies that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look,…
A certificate whose chromatogram axes do not match its stated method — one year on Replied, post #38 · Sourcing › Red flags · 4 Jun 2026 · 21 likes An unexplained discrepancy that the supplier declined to address is a legitimate thing to record, stated as exactly that and nothing more. I would rather say I do not…
A certificate whose chromatogram axes do not match its stated method — one year on Replied, post #27 · Sourcing › Red flags · 3 Jun 2026 · 8 likes The most useful contribution to this subcategory is a resolved case written up with the resolution, because the unresolved ones are all anyone remembers.
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? Replied, post #28 · Compounds › Repair & healing peptides · 29 May 2026 · 0 likes Worth separating two things that post #24 runs together. BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports…
Journal club: LEADER as the historical anchor Replied, post #77 · Evidence › Journal club · 21 May 2026 · 2 likes Counterpoint on LEADER, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #67 · Evidence › Journal club · 19 May 2026 · 17 likes Adding what did not work for me on orforglipron phase 2, since the failures never get written up and they are half the useful information.
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #22 · Compounds › Semaglutide · 10 May 2026 · 0 likes Post #21 describes the usual case. This is about the unusual one. Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they…
[2026 update] Does a peptide degrade silently, with no visual change? Replied, post #57 · Practice › Storage & stability · 9 May 2026 · 11 likes Clarity is a weak test. A solution can lose a significant fraction of its active content to degradation or adsorption while remaining perfectly clear. If anyone can…
Citation sweep results: how many references did not say what was claimed Replied, post #88 · Meta › Wiki maintenance · 2 May 2026 · 1 like Coming back to post #84, because the follow-up matters more than the original answer. Careful with that. A short duplicated paragraph is sometimes better than a link,…
Revisiting: Mobile reading experience on long topics Replied, post #4 · marked as the solution · Meta › Site feedback · 27 Apr 2026 · 11 likes Coming back to post #2, because the follow-up matters more than the original answer. Suggestion rather than complaint: the vendor pages carry a review date, and topics…
Publication bias detection and its low power — does this still hold? Replied, post #26 · Evidence › Meta-analyses · 26 Apr 2026 · 6 likes Post #23 answers the question as asked. The question underneath it is different. An observation about Publication bias detection that I cannot explain and am posting…
Subgroup analyses: pre-specified versus discovered — a second dataset Replied, post #57 · Evidence › Trials · 23 Apr 2026 · 25 likes Nobody has said the unglamorous part of Subgroup analyses yet, so: most of the variation is explained by things that are boring to write about and easy to check.
List price versus negotiated price versus what you pay Replied, post #23 · Access › Pricing · 9 Apr 2026 · 21 likes The most useful pricing posts here are the ones that show the arithmetic rather than the conclusion.
[2026 update] Charge states for a 4 kDa peptide, worked through Replied, post #59 · Analytics › Mass spectrometry · 6 Apr 2026 · 31 likes Noted, and I have changed what I was going to do on the strength of it.
Molecular mass of semaglutide and why the figure differs between sources Replied, post #27 · Compounds › Semaglutide · 30 Mar 2026 · 0 likes Understood. Thank you for being specific about the limits of it.
Travelling with an injectable: documentation and practicalities Replied, post #17 · Access › International · 24 Mar 2026 · 18 likes Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not…
Air bubbles in a subcutaneous injection: the honest risk assessment — does this still… Replied, post #24 · Practice › Administration · 22 Mar 2026 · 14 likes Coming back to post #22, because the follow-up matters more than the original answer. Air bubbles is a good example of a question where the honest answer is boring and…
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #40 · Data & Tools › Datasets · 20 Mar 2026 · 0 likes The arithmetic on community side-effect dataset is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone…
Subgroup analyses: pre-specified versus discovered — a second dataset Replied, post #13 · Evidence › Trials · 18 Mar 2026 · 2 likes My understanding of Subgroup analyses is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
The 2.5 mg starting dose is not a therapeutic dose — why that matters Replied, post #39 · Compounds › Tirzepatide · 9 Mar 2026 · 11 likes Picking up post #37: that is the part I would want checked first. Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound…
Run-in periods and the population they select Replied, post #76 · Evidence › Trials · 4 Mar 2026 · 1 like The version of run-in periods that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Citation sweep results: how many references did not say what was claimed Replied, post #54 · Meta › Wiki maintenance · 2 Mar 2026 · 0 likes Citation sweep results has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
[2026 update] Confounding by indication, explained with a concrete example Replied, post #78 · Evidence › Study critique · 23 Feb 2026 · 6 likes I had written a reply contradicting post #74 and deleted it. Here is what survived. Hold a trial to the standard something could actually have met. A criticism that no…
Second pass at: Choosing a concentration on purpose rather than by accident Replied, post #19 · Practice › Reconstitution · 20 Feb 2026 · 29 likes Picking up post #18: that is the part I would want checked first. Write the reconstitution date and the concentration on the vial. Not on a note, on the vial. Every…
Why a compound being unapproved is not the same as being illegal to possess Replied, post #60 · Sourcing › Regulatory · 17 Feb 2026 · 11 likes One more thing on compound being unapproved that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that,…
A parcel stationary at a customs facility for nine days Replied, post #30 · Sourcing › Logistics · 17 Feb 2026 · 9 likes A tracking gap at a customs facility is the most common cause of an unexpectedly long transit and the segment nobody has visibility of.
Pharmacy supply in the UK and the questions you will be asked Replied, post #43 · Regional › UK & Ireland · 16 Feb 2026 · 0 likes Post #42 is the version of this I will quote in future. One addition. My understanding of pharmacy supply is a few years old and may have been superseded. If it has…
Dizziness on standing and the electrolyte explanation — does this still hold? Replied, post #45 · Practice › Side effects · 12 Feb 2026 · 0 likes Worth separating two things that post #41 runs together. The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of…
Pharmacy supply in the UK and the questions you will be asked Replied, post #36 · Regional › UK & Ireland · 9 Feb 2026 · 0 likes The most useful contribution is a link to the current official page with the date you accessed it. That survives; a paraphrase does not. Caveat: everything above…
[2026 update] Confounding by indication, explained with a concrete example Replied, post #4 · Evidence › Study critique · 24 Jan 2026 · 0 likes Criticism is more useful when it is narrower. "The trial answers a different question from the one being asked" is actionable; "the trial is flawed" is not.
Coming back to: Reading a supplier's product description as a marketing document Replied, post #4 · Compounds › Other compounds · 23 Jan 2026 · 26 likes Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a…
Reading an interaction checker output critically Replied, post #96 · Practice › Interactions · 19 Jan 2026 · 0 likes Gastrointestinal symptoms from one compound can mask or mimic an interaction with another. Introducing two changes at once makes attribution impossible, which is an…
Muscle cramps: the ordinary causes before the exotic ones Replied, post #49 · Practice › Side effects · 17 Jan 2026 · 32 likes Noted, and I have changed what I was going to do on the strength of it.
Storing lyophilised material long term: what governs the shelf life Replied, post #27 · Practice › Storage & stability · 15 Jan 2026 · 1 like Reframing storing lyophilised material long term slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it…
Can a home kit substitute for a laboratory report? A careful no Replied, post #105 · Analytics › Home & field testing · 13 Jan 2026 · 1 like Answering the question post #103 raises rather than the one it answers. The honest cost comparison is a home kit against a single independent submission. For most…
Distinguishing expected GI effects from something that needs urgent attention Replied, post #25 · Practice › Side effects · 4 Jan 2026 · 26 likes Discontinuation for adverse effects in the published trials was not rare at the higher doses. That number belongs in any discussion of tolerability and is usually left…
Distinguishing expected GI effects from something that needs urgent attention Replied, post #18 · Practice › Side effects · 2 Jan 2026 · 15 likes Reflux and eructation are the two most under-reported effects in the first-hand accounts here, and both follow directly from delayed emptying.
Reverse causation in a cohort study of weight and outcome Replied, post #12 · Evidence › Study critique · 1 Jan 2026 · 32 likes A criticism that would apply equally to every trial in the field is worth stating once and is not a reason to discount a particular paper.
What "verified" means on our vendor pages, stated narrowly Replied, post #16 · Sourcing › Vendor reports · 28 Dec 2025 · 4 likes The cost of a submission is worth stating. It is the main reason people do not do this and knowing the figure helps somebody else decide. The short answer was in the…
The decimal-point error, and the habit that catches it Replied, post #46 · Practice › Reconstitution · 15 Dec 2025 · 0 likes Where the decimal-point error reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
A history of disordered eating: proceeding carefully Replied, post #25 · Wellbeing › Mental health · 10 Dec 2025 · 18 likes Adding a reference point for history of disordered eating. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be…
Robustness: the parameters worth deliberately varying Replied, post #49 · Analytics › Method validation · 8 Dec 2025 · 0 likes Two sentences on robustness and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow. What is inferred…
Comparing my trajectory with the trial curves, carefully Replied, post #77 · Outcomes › Progress reports · 17 Nov 2025 · 2 likes Post #76 and I disagree about the size of the effect, not about the direction. Menstrual cycle: for people who menstruate, weight can shift by several pounds across the…
Why "any advice?" is the least effective ending for a post — the long version Replied, post #83 · Start Here › How to Ask · 9 Nov 2025 · 11 likes Building on post #82 rather than restating it. Context that matters: compound, how long in, current dose, relevant history. Context that does not matter: how you feel,…
A parcel that arrived warm: a decision process, not a verdict Replied, post #125 · Practice › Storage & stability · 7 Nov 2025 · 15 likes Clarity is a weak test. A solution can lose a significant fraction of its active content to degradation or adsorption while remaining perfectly clear. I would treat the…
Adolescents: a distinct evidence base — one year on Replied, post #31 · Clinical › Special populations · 5 Nov 2025 · 16 likes Noted, and I have changed what I was going to do on the strength of it.
Liver enzymes drifting down and what that usually means Replied, post #24 · Clinical › Bloodwork · 3 Nov 2025 · 0 likes Narrowing post #22, because the general version has more than one answer. What I want from this liver enzymes drifting thread is the list of things that would need to…
EMA product information as a primary source Replied, post #12 · Regional › European Union · 29 Oct 2025 · 0 likes Appreciated. The plain phrasing does more work here than a longer post would.
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Replied, post #88 · Compounds › Tirzepatide · 23 Oct 2025 · 23 likes Noted, and thank you for writing it out rather than summarising it.
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #84 · Start Here › Welcome · 20 Oct 2025 · 10 likes Quietly grateful for the plain phrasing. Not every thread gets that.
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #61 · Start Here › Welcome · 18 Oct 2025 · 0 likes Reading counts toward trust level, so lurking is not wasted. That is unusual and it is the reason the levels here track familiarity rather than volume. The reasoning is…
Detection wavelength and why 214 nm and 280 nm disagree Replied, post #63 · Analytics › HPLC & UHPLC · 12 Oct 2025 · 14 likes Agreed on detection wavelength, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does…
Pinch or no pinch, and how needle length changes the answer Replied, post #78 · Practice › Administration · 25 Sep 2025 · 5 likes The question underneath pinch is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it. Write down what you would expect to…
Payment method and the leverage it gives you, ranked Replied, post #20 · Sourcing › Payments · 16 Sep 2025 · 0 likes Bank transfer and finality: once a bank transfer is sent, it is final. The money is gone. There is no recourse with the bank if the supplier disappears. That is why…
Are there stupid questions here? A staff answer, at length Replied, post #152 · Start Here › Welcome · 4 Sep 2025 · 0 likes That is a cleaner way of putting what I was circling around.
Power cut for eleven hours: how I assessed it afterwards Replied, post #45 · Practice › Storage & stability · 4 Sep 2025 · 8 likes The documentation on power cut for eleven hours is better than this thread and I say that as someone who has posted in the thread.
Coming back to: Resolution and tailing factor: real acceptance criteria Replied, post #54 · Analytics › HPLC & UHPLC · 31 Aug 2025 · 0 likes Peak purity: a diode-array detector records a spectrum at every time point. If a peak contains two co-eluting species with different spectra, the spectrum changes…
Fatigue in the first month: how much is the drug and how much is intake — what changed… Replied, post #64 · Practice › Side effects · 31 Aug 2025 · 0 likes Post #61 is right about the mechanism and I think understates the practical bit. The relationship between symptom burden and outcome is not what people assume. Feeling…
Promotion criteria, and the one that stops most nominations — the long version Replied, post #47 · Documentation › Doc review · 26 Aug 2025 · 15 likes The arithmetic in post #46 is right; the assumption feeding it is the part to check. The bit of Promotion criteria that nobody enjoys is that the answer changes…
The "under review" status pill and when a moderator applies it — a second dataset Replied, post #45 · Evidence › Preprints · 25 Aug 2025 · 0 likes If you cite a preprint in a maintained document here, the convention is to label it in the sentence and to note the check date. The document review will catch the…
Lyophilisation and why the cake looks the way it does Replied, post #13 · Pharmacology › Formulation chemistry · 23 Aug 2025 · 0 likes Nothing to add, except that this is the answer I would give if asked.
What a documentation review can and cannot tell you Replied, post #74 · Sourcing › Independent verification · 15 Aug 2025 · 0 likes Confirming post #71 from a second method, which matters more than confirming it from a second person. Two claims get bundled together under documentation review and…
Anxiety in the first weeks: drug, situation, or both — what changed since Replied, post #14 · Wellbeing › Mental health · 9 Aug 2025 · 0 likes Nothing here is medical advice and several members in this subcategory say plainly that they are describing their own experience only.
A ten-fold dose error caught before injection — one year on Replied, post #67 · Devices › Syringes & needles · 3 Aug 2025 · 20 likes Taking post #64 at face value and following it one step further. Barrel size determines resolution and nothing else. A 0.3 mL barrel and a 1 mL barrel deliver the same…
Column chemistry choices for a 40-residue peptide Replied, post #6 · Analytics › HPLC & UHPLC · 2 Aug 2025 · 3 likes Adding the measurement that post #3 says would settle it. Reversed-phase separates on hydrophobicity. A peptide is retained on a non-polar stationary phase and eluted…
[2026 update] What we do not know about retatrutide, listed explicitly Replied, post #25 · Compounds › Retatrutide · 27 Jul 2025 · 19 likes Building on post #22 rather than restating it. No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a…
Semaglutide versus liraglutide head to head: reading STEP 8 carefully Replied, post #28 · Compounds › Semaglutide · 17 Jul 2025 · 0 likes On post #27 — agreed on the reasoning, with one qualification. The documentation on semaglutide versus liraglutide is better than this thread and I say that as someone…
Adolescents: a distinct evidence base — one year on Replied, post #3 · Clinical › Special populations · 16 Jul 2025 · 2 likes Confirming the opening post from a second method, which matters more than confirming it from a second person. Two people in this thread mean different things by…
Revisiting: Reading a denial letter as a specification for your appeal Replied, post #46 · Access › Insurance & coverage · 16 Jul 2025 · 9 likes I read post #42 twice before replying, because I had assumed the opposite. A clinician's supporting letter that addresses the criteria explicitly is worth considerably…
A field-by-field walk through a certificate of analysis Replied, post #27 · Analytics › COA interpretation · 15 Jul 2025 · 5 likes The most useful reply I ever got about field-by-field walk through a certificate was a request to state my units. It sounds like pedantry and it has saved me twice.
A field-by-field walk through a certificate of analysis Replied, post #5 · Analytics › COA interpretation · 14 Jul 2025 · 10 likes Two claims get bundled together under field-by-field walk through a certificate and they need separating. The descriptive one — this is what was observed — is usually…
An emergency department visit, described afterwards Replied, post #40 · Safety › Adverse events · 9 Jul 2025 · 0 likes I read post #39 twice before replying, because I had assumed the opposite. If someone has run emergency department visit properly I would rather read that than my own…
Follow-up: Glucagon receptor agonism in a weight-loss compound Replied, post #2 · Pharmacology › Receptor biology · 29 Jun 2025 · 6 likes Taking the opening post at face value and following it one step further. GIP receptor signalling: the glucose-dependent insulinotropic peptide receptor (GIP) is…
Asking about a compound your prescriber has not heard of Replied, post #78 · Clinical › Prescriber conversations · 27 Jun 2025 · 17 likes Asking about monitoring: understand what lab work will be done, how often, and what you will be monitored for. A plan is better than ad-hoc monitoring. I would put a…
BPC-157: what the rodent literature actually shows, and what it does not — a second… Replied, post #61 · Compounds › Repair & healing peptides · 23 Jun 2025 · 0 likes Distinguishing three things in the BPC-157 discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets…
Validating a calculator against hand arithmetic — what changed since Replied, post #137 · Data & Tools › Calculators · 15 Jun 2025 · 21 likes Post #135 is the version of this I will quote in future. One addition. The calculators maintained on this site are open-source and verifiable. They are intended to…
Whether an aggregate is worth publishing at all: a disputed topic Replied, post #4 · Data & Tools › Datasets · 15 Jun 2025 · 27 likes Publishing the raw records alongside the summary is what makes a dataset checkable. A summary alone asks for trust that nobody has earned.
[2026 update] An appeal that failed, and what I would do differently Replied, post #103 · Access › Insurance & coverage · 14 Jun 2025 · 14 likes I had written a reply contradicting post #101 and deleted it. Here is what survived. Checked the appeal claim against the primary source this morning. It survives, with…
Splitting a vial for two laboratories: how to do it without ruining both Replied, post #57 · Sourcing › Independent verification · 8 Jun 2025 · 9 likes The arithmetic in post #56 is right; the assumption feeding it is the part to check. Method has to travel with the number. A verification record without the method is…
Second pass at: Retatrutide mass and identity: what a report should show Replied, post #38 · Compounds › Retatrutide · 8 May 2025 · 24 likes Worth separating two things that post #36 runs together. What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose…
Checking someone else's arithmetic: a worked example thread Replied, post #41 · Practice › Reconstitution · 24 Apr 2025 · 2 likes Preservative effectiveness is tested against a defined microbial challenge under defined conditions. It is not a licence to treat an entered vial as sterile…
A certificate with no method stated: what can you conclude? Replied, post #36 · Analytics › COA interpretation · 6 Apr 2025 · 2 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
Coverage for the indication versus for the drug — a second dataset Replied, post #51 · Access › Insurance & coverage · 29 Mar 2025 · 6 likes Post #47 and I disagree about the size of the effect, not about the direction. Formulary status: the list of covered medications and the tier (how much you pay) they…
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #27 · Compounds › Retatrutide · 20 Mar 2025 · 10 likes Taking post #26 at face value and following it one step further. Agreed on Triple agonism, with one qualification that I think matters. The reasoning holds for the case…
Revisiting: Bug report: the reconstitution calculator and a rounding edge case Replied, post #122 · Data & Tools › Calculators · 10 Mar 2025 · 0 likes Answering the question post #119 raises rather than the one it answers. Tools that run entirely in the browser send nothing anywhere, which matters more to some people…
Pharmaceutical compounding rules, summarised from primary sources Replied, post #150 · Sourcing › Regulatory · 6 Mar 2025 · 0 likes Read the primary regulatory document rather than a summary of it. Summaries in this area lag by a year routinely and by longer occasionally. The part I am sure of is…
Reading order for a first week here, and what to skip until later Replied, post #13 · Start Here › Welcome · 23 Feb 2025 · 1 like I would rather this thread reach "we do not know" about reading order than reach a confident answer that nobody can support when asked.
Adducts: sodium, potassium, and the peak you did not expect Replied, post #11 · Analytics › Mass spectrometry · 15 Feb 2025 · 7 likes This follows post #9 rather than contradicting it. Adducts: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I…
Specification in the result column: why that is a meaningful error — the long version Replied, post #14 · Analytics › COA interpretation · 11 Feb 2025 · 7 likes Post #12 put the caveat in the right place and I want to underline it. A chromatogram supplied as a small image is legible for peak shape and not for baseline detail.…
Second pass at: Manufacturer assistance programmes and their eligibility rules Replied, post #4 · Access › Pricing · 6 Feb 2025 · 29 likes The arithmetic in post #3 is right; the assumption feeding it is the part to check. Worth stating the null on Manufacturer assistance programmes before we explain it:…
Distinguishing a deletion sequence by mass alone Replied, post #45 · Analytics › Mass spectrometry · 3 Feb 2025 · 5 likes Resolution and mass accuracy are different specifications. An instrument can resolve two species and still assign their masses imprecisely, and the reverse is also…
Biased agonism: a real phenomenon, an over-used explanation — what changed since Replied, post #29 · Pharmacology › Receptor biology · 19 Jan 2025 · 0 likes The reason Biased agonism is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is…
An orphaned page with no inbound links Replied, post #2 · Meta › Wiki maintenance · 18 Jan 2025 · 1 like The opening post is the version of this I will quote in future. One addition. Adding the boring version of orphaned page, because the interesting version keeps getting…
Reporting a good result: why nobody bothers and why they should — one year on Replied, post #23 · Sourcing › Vendor reports · 16 Jan 2025 · 13 likes Multiple services on one lot: agreement across two independent laboratories is stronger than a high number from one. Our vendor pages deliberately mix services for that…
Research-use-only labelling: what it means and what it does not — the long version Replied, post #64 · Sourcing › Regulatory · 15 Jan 2025 · 0 likes On post #60 — agreed on the reasoning, with one qualification. Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if…
[2026 update] New subcategory: rationale and scope Replied, post #124 · Meta › Announcements · 6 Jan 2025 · 1 like I read post #122 twice before replying, because I had assumed the opposite. Last note on this: announcements here get more replies than most topics and almost all of…
Semaglutide in people without diabetes: what the evidence base looks like Replied, post #5 · Compounds › Semaglutide · 25 Dec 2024 · 1 like That matches what I have seen, for whatever a single anecdote is worth.
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #106 · Compounds › Tirzepatide · 24 Dec 2024 · 4 likes Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose…
Anxiety in the first weeks: drug, situation, or both Replied, post #29 · Wellbeing › Mental health · 21 Dec 2024 · 19 likes Expectations set by other people's reported trajectories are a documented source of distress, and the trajectories posted are not representative.
A side-effect grading scheme this community uses, and its limits — the long version Replied, post #15 · Practice › Side effects · 20 Nov 2024 · 31 likes The reason side-effect grading scheme keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is…
Injection-site reactions: describing them precisely enough to be useful Started this topic · Practice › Side effects · 11 Nov 2024 · 2 likes Injection-site reactions: describing them precisely enough to be useful Writing it up because I had to work it out twice and would rather nobody else did. Trying to…
US compounding rules and how they changed Replied, post #64 · Regional › North America · 9 Nov 2024 · 30 likes Picking up post #63: that is the part I would want checked first. The public assessment documents published at approval are free, detailed and largely unread here.
Choosing which test to pay for, given a fixed budget — does this still hold? Replied, post #16 · Sourcing › Independent verification · 1 Nov 2024 · 0 likes The record shows what was measured. Everything beyond that is inference and this site tries to keep the line visible.
A revision dispute resolved on the topic rather than in the history — a second dataset Replied, post #7 · Meta › Wiki maintenance · 12 Oct 2024 · 6 likes Narrowing post #6, because the general version has more than one answer. Revision dispute resolved is a question about a distribution, not about a value, and treating…
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #92 · Clinical › Bloodwork · 8 Oct 2024 · 2 likes Sample handling before analysis affects several analytes, and a haemolysed sample produces predictable artefacts that a laboratory will usually comment on. Posting it…
Pen wastage and its effect on real cost Replied, post #30 · Access › Pricing · 1 Oct 2024 · 10 likes Prices in old topics are historical records and are frequently wrong now. Every post here carries its date for that reason. Noting that the question and the thing…
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #17 · Compounds › Semaglutide · 28 Sep 2024 · 0 likes Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about…
Meeting a protein target on a suppressed appetite — one year on Replied, post #5 · Nutrition & Training › Protein & intake · 6 Sep 2024 · 5 likes Post #3 and I disagree about the size of the effect, not about the direction. Maintenance changes the calculation and almost nobody revisits their target when they get…
Progressive overload when the scale is falling — one year on Replied, post #23 · Nutrition & Training › Resistance training · 3 Sep 2024 · 30 likes I think the Progressive overload question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Correlation in a self-tracked dataset: what it can support Replied, post #148 · Research Methods › Statistics · 25 Aug 2024 · 5 likes That matches what I have seen, for whatever a single anecdote is worth.
Follow-up: Where the four-week escalation interval comes from, and what it is not Replied, post #44 · Practice › Dosing & titration · 13 Aug 2024 · 21 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.…
Guidelines revision: what changed and why Replied, post #118 · Meta › Announcements · 28 Jul 2024 · 0 likes Confirming post #117 from a second method, which matters more than confirming it from a second person. Reporting rather than recommending, on guidelines revision. What…
Follow-up: Conditions that change the calculus rather than forbidding it Replied, post #27 · Safety › Contraindications · 23 Jul 2024 · 3 likes Adding the boring version of Conditions, because the interesting version keeps getting posted and the boring one is usually right. Check the ordinary explanations, in…
Follow-up: Where the four-week escalation interval comes from, and what it is not Replied, post #31 · Practice › Dosing & titration · 21 Jul 2024 · 5 likes The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you…
Promotion criteria, and the one that stops most nominations Replied, post #10 · Documentation › Doc review · 30 Jun 2024 · 2 likes Reviewing your own nomination is fine and is not sufficient. Somebody else has to read it for the process to mean anything. Stating my assumptions rather than smuggling…
Cold packs, phase-change material, and what survives ten days Replied, post #49 · Sourcing › Logistics · 27 Jun 2024 · 22 likes Answering the question post #45 raises rather than the one it answers. Two sentences on cold packs and then I will stop, because the rest is speculation and the thread…
Reading a meta-analysis you disagree with, fairly Replied, post #2 · Evidence › Meta-analyses · 23 Jun 2024 · 0 likes Reading the pooled figure without reading the inclusion criteria is the equivalent of quoting a trial without its population. Both are common and both are avoidable.…